BRIEF-Clearside Biomedical Announces 6-Month Results From Oasis Extension Study

Reuters2023-02-02

Feb 2 (Reuters) - Clearside Biomedical Inc :

* CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE 6-MONTH RESULTS FROM OASIS EXTENSION STUDY WITH SUPRACHOROIDAL CLS-AX IN WET AMD

* CLEARSIDE BIOMEDICAL INC - 67% OF EXTENSION STUDY PARTICIPANTS WENT AT LEAST 6 MONTHS WITHOUT NEEDING ADDITIONAL TREATMENT

* CLEARSIDE BIOMEDICAL INC - EXTENSION PARTICIPANTS EXPERIENCED A 77 - 85% REDUCTION IN TREATMENT BURDEN OVER 6 MONTHS

* CLEARSIDE BIOMEDICAL- EXPECT TO INITIATE RANDOMIZED, CONTROLLED, DOUBLE-MASKED, PHASE 2B CLINICAL TRIAL, CALLED ODYSSEY, IN Q1 THIS YEAR

* CLEARSIDE BIOMEDICAL INC - PRIMARY ENDPOINT READOUT ANTICIPATED IN MID-2024

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2308239100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-02-02 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2308239100","market":"us","top_or_hot":-1,"title":"BRIEF-Clearside Biomedical Announces 6-Month Results From Oasis Extension Study","media":"Reuters","content":"<html><body><p>Feb 2 (Reuters) - Clearside Biomedical Inc   :</p><p>   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE 6-MONTH RESULTS FROM OASIS EXTENSION STUDY WITH SUPRACHOROIDAL CLS-AX IN WET AMD</p><p>   * CLEARSIDE BIOMEDICAL INC - 67% OF EXTENSION STUDY PARTICIPANTS WENT AT LEAST 6 MONTHS WITHOUT NEEDING ADDITIONAL TREATMENT</p><p>   * CLEARSIDE BIOMEDICAL INC - EXTENSION PARTICIPANTS EXPERIENCED A 77 - 85% REDUCTION IN TREATMENT BURDEN OVER 6 MONTHS</p><p>   * CLEARSIDE BIOMEDICAL-  EXPECT TO INITIATE RANDOMIZED, CONTROLLED, DOUBLE-MASKED, PHASE 2B CLINICAL TRIAL, CALLED ODYSSEY, IN Q1 THIS YEAR</p><p>   * CLEARSIDE BIOMEDICAL INC -  PRIMARY ENDPOINT READOUT ANTICIPATED IN MID-2024</p><p>Source text for Eikon:    Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Clearside Biomedical Announces 6-Month Results From Oasis Extension Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Clearside Biomedical Announces 6-Month Results From Oasis Extension Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-02 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Feb 2 (Reuters) - Clearside Biomedical Inc   :   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE 6-MONTH RESULTS FROM OASIS EXTENSION STUDY WITH SUPRACHOROIDAL CLS-AX IN WET AMD   * CLEARSIDE BIOMEDICAL INC...</p>\n\n<a href=\"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4213","symbol_name":"石油与天然气的勘探与生产","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2308239100","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2308239100","pubTimestamp":1675344126,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Feb 2 (Reuters) - Clearside Biomedical Inc   :   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE 6-MONTH R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4213":"石油与天然气的勘探与生产","BK4007":"制药","CLSD":"Clearside Biomedical Inc."},"translate_title":"简介-Clearside Biomedical宣布Oasis扩展研究的6个月结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLSD":1,"OAS":1},"content_text":"Feb 2 (Reuters) - Clearside Biomedical Inc   :   * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE 6-MONTH RESULTS FROM OASIS EXTENSION STUDY WITH SUPRACHOROIDAL CLS-AX IN WET AMD   * CLEARSIDE BIOMEDICAL INC - 67% OF EXTENSION STUDY PARTICIPANTS WENT AT LEAST 6 MONTHS WITHOUT NEEDING ADDITIONAL TREATMENT   * CLEARSIDE BIOMEDICAL INC - EXTENSION PARTICIPANTS EXPERIENCED A 77 - 85% REDUCTION IN TREATMENT BURDEN OVER 6 MONTHS   * CLEARSIDE BIOMEDICAL-  EXPECT TO INITIATE RANDOMIZED, CONTROLLED, DOUBLE-MASKED, PHASE 2B CLINICAL TRIAL, CALLED ODYSSEY, IN Q1 THIS YEAR   * CLEARSIDE BIOMEDICAL INC -  PRIMARY ENDPOINT READOUT ANTICIPATED IN MID-2024Source text for Eikon:    Further company coverage:   ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2308239100"}